| Literature DB >> 29403399 |
Henner Hanssen1, Alice Minghetti1, Oliver Faude1, Arno Schmidt-Trucksäss1, Lukas Zahner1, Johannes Beck2, Lars Donath1,3.
Abstract
BACKGROUND: Psychiatric disorders are associated with a higher prevalence of cardiovascular disease and mortality. Regular exercise has been shown to reduce depressive symptoms and improve arterial stiffness as a biomarker of cardiovascular risk. We aimed to investigate the effects of different exercise modalities on depression severity index and arterial stiffness in patients suffering from unipolar depression.Entities:
Keywords: arterial stiffness; cardiovascular risk; depression; high-intensity exercise training; prevention
Year: 2018 PMID: 29403399 PMCID: PMC5786741 DOI: 10.3389/fpsyt.2017.00311
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Figure 1Flow Chart of the Randomized Controlled Trial.
Baseline data of the participants for both intervention groups (HILV and MCT).
| HILV ( | MCT ( | |
|---|---|---|
| Gender [m/f] | 5/14 | 4/11 |
| Age [years] | 38.1 (12.2) | 37.5 (10.1) |
| BMI [kg m−2] | 22.6 (3.3) | 24.9 (5.2) |
| Systolic BP [mmHg] | 120.1 (10.5) | 115.9 (11.2) |
| Diastolic BP [mmHg] | 97.4 (8.7) | 92.9 (10.0) |
| BDI-II [score] | 28.8 (9.5) | 33.8 (8.5) |
Data are provided as means with SDs.
Gender is indicated as f, female; m, male; BMI, body mass index; BP, blood pressure; BDI-II, Beck-Depression-Inventory second edition, expressed in BDI-II score; HILV, high-intensity low volume.
Medication use in high-intensity low volume (HILV) and MCT.
| HILV ( | MCT ( | |
|---|---|---|
| SNRIs | 4 | 5 |
| Venlafaxin (75, 175, 225 mg) | 2 | 4 |
| Mirtzapin (7.5, 15, 30 mg) | 2 | 0 |
| Wellbutrin (150 mg) | 0 | 1 |
| SSRIs | 10 | 13 |
| Trittico (25, 50, 100 mg) | 2 | 4 |
| Escitalopram (10, 20 mg) | 5 | 5 |
| Citalopram (20 mg) | 1 | 2 |
| Fluoxetin (20, 40 mg) | 0 | 2 |
| Paroxetin (20 mg) | 1 | 0 |
| Cipralex (60 mg) | 1 | 0 |
| Seralin (50 mg) | 0 | 0 |
| Atypical neuroleptic medication | 3 | 3 |
| Quetiapin (25, 50, 150, 300 mg) | 1 | 2 |
| Truxal (15 mg) | 2 | 1 |
Pre and post intervention results of both groups for peripheral and central vessel parameters and arterial stiffness parameters.
| Pre mean (SD) | Post mean (SD) | SMD Cohen’s d | ANCOVA | |||
|---|---|---|---|---|---|---|
| BDI-II | HILV | 28.8 (9.5) | 15.5 (8.5) | 1.48 | 0.07 | 0.10 |
| MCT | 33.8 (8.5) | 22.6 (7.5) | 1.40 | |||
| pSBP [mmHg] | HILV | 120.1 (10.5) | 119.4 (12.6) | −1.50 | 0.94 | 0.0 |
| MCT | 115.9 (11.2) | 116.0 (12.3) | −0.01 | |||
| pDBP [mmHg] | HILV | 78.1 (8.0) | 76.5 (8.8) | 0.19 | 0.59 | 0.01 |
| MCT | 73.4 (10.4) | 72.9 (13.2) | 0.04 | |||
| cSBP [mmHg] | HILV | 112.7 (10.8) | 111.3 (13.2) | 0.12 | 1.0 | 0 |
| MCT | 109.4 (12.0) | 108.9 (13.5) | 0.04 | |||
| cDBP [mmHg] | HILV | 78.7 (8.3) | 77.0 (8.9) | 0.20 | 0.42 | 0.21 |
| MCT | 74.0 (10.3) | 74.0 (13.2) | 0 | |||
| cPP [mmHg] | HILV | 34.0 (6.2) | 34.3 (8.7) | −0.04 | 0.94 | 0 |
| MCT | 35.5 (9.1) | 35.0 (8.3) | 0.06 | |||
| AIx [%] | HILV | 25.9 (12.4) | 24.5 (12.6) | 0.11 | 0.39 | 0.02 |
| MCT | 34.1 (13.8) | 23.0 (15.0) | 0.77 | |||
| AIx@75 [%] | HILV | 19.5 (10.9) | 18.6 (10.5) | 0.08 | 0.17 | 0.06 |
| MCT | 23.0 (13.6) | 14.6 (13.8) | 0.61 | |||
| PWV [m/s] | HILV | 6.1 (1.1) | 6.1 (1.2) | 0 | 0.57 | 0.01 |
| MCT | 5.9 (0.9) | 5.9 (1.0) | 0 | |||
| VO2max [ml/min/kgBW] | HILV | 34.7 (8.5) | 35.6 (8.7) | −0.10 | 0.63 | 0.08 |
| MCT | 30.1 (6.0) | 30.7 (6.3) | −0.10 | |||
All results depicted as mean and SD.
BDI-II, Beck Depression Inventory-II; pSBP, peripheral systolic blood pressure; pDBP, peripheral diastolic blood pressure; cSBP, central systolic blood pressure; cDBP, central diastolic blood pressure; cPP, central pulse pressure; AIx, Augmentation index; AIx@75, Augmentations index corrected for 75 beats per minute; PWV, pulse wave velocity; VO.
Parallel group trials for HILV and MCT.
| Maximal parameters | Differences in means | Standardized mean difference [90% CI] | Probability for a practically worthwhile effect |
|---|---|---|---|
| BDI-II Score | |||
| HILV vs. MCT | −4.3 [−8.3; −0.4] | −0.45 [−0.85; −0.04] | 85%; likely beneficial |
| pSBP [mmHg] | |||
| HILV vs. MCT | 0.4 [−5.7; 6.5] | 0.03 [−0.50; 0.57] | 24%; unlikely beneficial |
| pDBP [mmHg] | |||
| HILV vs. MCT | −1.2 [−5.0; 2.7] | −0.12 [−0.51; 0.27] | 38%; possibly beneficial |
| cSBP [mmHg] | |||
| HILV vs. MCT | 0.0 [−6.5; 6.5] | 0.00 [−0.55; 0.55] | 28%; possibly beneficial |
| cDBP [mmHg] | |||
| HILV vs. MCT | −1.7 [−5.5; 2.0] | −0.18 [−0.56; 0.21] | 48%; possiblybeneficial |
| cPP [mmHg] | |||
| HILV vs. MCT | 0.2 [−4.0; 4.5] | 0.03 [−0.51; 0.57] | 25%; unlikely beneficial |
| AIx [%] | |||
| HILV vs. MCT | 4.1 [−0.5; 12.7] | 0.29 [−0.32; 0.90] | 9%; unlikely beneficial |
| MCT vs. HILV | −4.1 [−12.7; 4.5] | −0.29 [−0.90; 0.32] | 61%; possibly beneficial |
| AIx@75 [%] | |||
| HILV vs. MCT | 5.5 [−1.4; 12.3] | 0.43 [−0.11; 0.97] | 3%; very unlikely beneficial |
| MCT vs. HILV | −0.8 [−9.1; 7.4] | −0.06 [−0.71; 0.59] | 37%; possiblybeneficial |
| PWV [m/s] | |||
| HILV vs. MCT | −0.1 [−0.3; 0.2] | −0.07 [−0.30; 0.16] | 18%; unlikely beneficial |
| VO2max [ml/min/kgBW] | |||
| HILV vs. MCT | 0.6 [−1.2; 2.5] | 0.08 [−0.15; 0.31] | 20%; unlikely beneficial |
Parallel group trials difference in means as well as standardized mean differences (90% confidence intervals) is given for BDI-II scores, central hemodynamic as well as arterial stiffness parameters. The probability for an effect being practically beneficial was calculated according to the magnitude-based inference method.
BDI-II, Beck Depression Inventory-II; pSBP, peripheral systolic blood pressure; pDBP, peripheral diastolic blood pressure; cSBP, central systolic blood pressure; cDBP, central diastolic blood pressure; cPP, central pulse pressure; AIx, Augmentation index; AIx@75, Augmentations index corrected for 75 beats per minute; PWV, pulse wave velocity; VO.